0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

NEW DRUGS FOR PATIENTS WITH EMOTIONAL DISORDERS

JAMA. 1955;157(8):665. doi:10.1001/jama.1955.02950250039012.
Text Size: A A A
Published online

ABSTRACT

Several drugs have been developed within recent years that appear to be valuable in the treatment of patients with emotional disorders. These include reserpine, other extracts of rauwolfia serpentina, and chlorpromazine ( 10-[γ-dimethylaminopropyl]-2-chlorophenothiazine hydrochloride), all of which are reported to have a sedative effect without clouding consciousness. Pipradrol (α-[2-piperidyl]-benzhydrol hydrochloride), another drug recently introduced, is being prescribed for its beneficial effect on feelings of depression. These drugs appear to offer advantages over drugs of long-standing usage, such as the barbital compounds, amphetamine, and methamphetamine, and to have somewhat different indications. Their use by both psychiatrists and nonpsychiatrists has been encouraged through circulars from pharmaceutical firms. Patients sometimes ask for them as a result of enthusiastic but uncritical attention these drugs have been given in the lay press. Any measure that can help patients suffering from emotional disorders is very welcome to the psychiatrist and general practitioner; however, a word of caution

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();